Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 18/20 | 1.00 |
| ▸ | ATP4B | P51164 | 18/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL825891 | 0.83 | ATP4A (1.00) | ATP4AATP4B | |
| Bromide SCHEMBL826517 | 0.83 | ATP4A (0.73) | ATP4AATP4BMAPTNPC1RAB9A | |
| Bromide SCHEMBL826740 | 0.83 | ATP4A (0.73) | ATP4AATP4BMAPTNPC1RAB9A | |
| SCHEMBL10672113 | 0.83 | ATP4A (0.74) | ATP4AATP4BMAPTNPC1RAB9A | |
| Bromide SCHEMBL826907 | 0.82 | MAPT (0.97) | ATP4AATP4BMAPTNPC1RAB9A | |
| Bromide SCHEMBL825847 | 0.82 | ATP4A (0.97) | ATP4AATP4BMAPTNPC1RAB9A | |
| SCHEMBL28902765 | 0.82 | ATP4A (0.72) | ATP4AATP4BMAPTNPC1RAB9A | |
| SCHEMBL28484315 | 0.82 | ATP4A (0.72) | ATP4AATP4BMAPTNPC1RAB9A | |
| Bromide SCHEMBL7142455 | 0.81 | ATP4A (0.70) | ATP4AATP4BMAPTNPC1RAB9A | |
| SCHEMBL823907 | 0.81 | ATP4A (1.00) | ATP4AATP4BMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179201-A1 | NOVEL THIAZOLE-BASED COMPOUND AND INHIBITOR OF T-TYPE CALCIUM CHANNEL CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-07-15 | — | — | US | claimed |
| WO-2008018655-A1 | NOVEL THIAZOLE-BASED COMPOUND AND INHIBITOR OF T-TYPE CALCIUM CHANNEL CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-02-14 | — | — | WO | claimed |
| US-8143296-B2 | Thiazole-based compound and inhibitor of T-type calcium channel containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-03-27 | — | — | US | disclosed |
| US-20100179201-A1 | NOVEL THIAZOLE-BASED COMPOUND AND INHIBITOR OF T-TYPE CALCIUM CHANNEL CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-07-15 | — | — | US | disclosed |
| WO-2008018655-A1 | NOVEL THIAZOLE-BASED COMPOUND AND INHIBITOR OF T-TYPE CALCIUM CHANNEL CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179201-A1 | NOVEL THIAZOLE-BASED COMPOUND AND INHIBITOR OF T-TYPE CALCIUM CHANNEL CONTAINING THE SAME | CACNA1G, CACNA1I, CACNA1H | ATP4A 169/4885ATP4B 393/4885MAPT 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.